Studies have shown that IL-13Rα2 is overexpressed in prostate cancer cells, suggesting that it could be used both as a potential biomarker and also as a potentially important therapeutic target for preventing cancer progression [13,76,77]. Here, IL13RA2 is linked to prostate carcinoma.